# A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

> **NCT07110883** · PHASE1 · RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SYS6023

## Key facts

- **NCT ID:** NCT07110883
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2026-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110883, "A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07110883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*